TRAILblazing Strategies for Cancer Treatment
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
In the late 1990s, tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF-family, started receiving much attention for its potential in cancer therapy, due to its capacity to induce apoptosis selectively in tumour cells in vivo. TRAIL binds to its membrane-bound death receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5) inducing the formation of a death-inducing signalling complex (DISC) thereby activating the apoptotic cascade. The ability of TRAIL to also induce apoptosis independently of p53 makes TRAIL a promising anticancer agent, especially in p53-mutated tumour entities. Thus, several so-called TRAIL receptor agonists (TRAs) were developed. Unfortunately, clinical testing of these TRAs did not reveal any significant anticancer activity, presumably due to inherent or acquired TRAIL resistance of most primary tumour cells. Since the potential power of TRAIL-based therapies still lies in TRAIL’s explicit cancer cell-selectivity, a desirable approach going forward for TRAIL-based cancer therapy is the identification of substances that sensitise tumour cells for TRAIL-induced apoptosis while sparing normal cells. Numerous of such TRAIL-sensitising strategies have been identified within the last decades. However, many of these approaches have not been verified in animal models, and therefore potential toxicity of these approaches has not been taken into consideration. Here, we critically summarise and discuss the status quo of TRAIL signalling in cancer cells and strategies to force tumour cells into undergoing apoptosis triggered by TRAIL as a cancer therapeutic approach. Moreover, we provide an overview and outlook on innovative and promising future TRAIL-based therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The AMPK signalling pathway coordinates cell growth, autophagy and metabolism
Mihaylova, M. M., & Shaw, R. J. (2011) · Nature Cell Biology · doi:10.1038/ncb2329 · Cited by 2,923
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900 · cited 7×
“The receptor-binding domain (aa 114–281) is located in the extracellular portion [1] which is cleaved from the cell surface to form bell-shaped homo-trimers.”
BackgroundInfluentialInduction of TNF receptor I-mediated apoptosis via two sequential signaling complexes
Micheau, O., & Tschopp, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00521-x · Cited by 2,738 · cited 1×
“Changes in c-FLIP [155,161,162] and caspase-8 ratio [163] can trigger cell death-independent cellular responses via a cytosolic signalling complex termed complex II [164].”
BackgroundA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 1×
“The rate of higher-grade adverse effects had been certainly lower compared to the treatment with first-line therapy for MM such as bortezomib [129] demonstrating a comparatively low toxicity of the treatment regimen.”
ResultTumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497 · cited 5×
“A hepatoxicity of LZ- and iz-TRAIL, however, could be excluded and a safe in vivo application has been performed [3,120,231].”
BackgroundInfluentialPUMA, a Novel Proapoptotic Gene, Is Induced by p53
Nakano, K., & Vousden, K. H. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00214-3 · Cited by 2,315 · cited 1×
“Autophagy controls the timing and efficiency of TRAIL-induced MOMP by the level of autophagy-releasing p53 upregulated modulator of apoptosis (PUMA, also known as Bcl-2-binding component 3) [215], a proapoptotic BH3-only Bcl-2 family member and downstream target of p53.”
BackgroundSafety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Self-consumption: the interplay of autophagy and apoptosis
Mariño, G., Niso-Santano, M., Baehrecke, E. H., & Kroemer, G. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3735 · Cited by 2,172 · cited 2×
“Beclin 1 (autophagy-related gene 6, ATG6) holds a vital role in the surveillance of autophagic actions [202,203] and the crosstalk between apoptosis and autophagy [198].”
BackgroundRabinowitz, J. D., & White, E. (2010) · Science · doi:10.1126/science.1193497 · Cited by 1,982 · cited 1×
“Apoptosis and autophagy are both stimulated in response to metabolic stressors, however, in tumour cells, a different picture emerges, and the dialogue between autophagy and apoptosis is disrupted [193,205,206].”
BackgroundTumor microenvironment and therapeutic response
Wu, T., & Dai, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.01.043 · Cited by 1,802
Hypoxia signalling in cancer and approaches to enforce tumour regression
Pouysségur, J., Dayan, F., & Mazure, N. M. (2006) · Nature · doi:10.1038/nature04871 · Cited by 1,676 · cited 1×
“Most solid tumours exhibit areas permanently or transiently under hypoxic conditions resulting from abnormal vascularisation and blood flow [217].”
BackgroundMolecular definitions of autophagy and related processes
Galluzzi, L., Baehrecke, E. H., Ballabio, A., Boya, P., Bravo‐San Pedro, J. M., Cecconi, F., Choi, A. M., Chu, C. T., Codogno, P., Colombo, M. I., et al. (2017) · The EMBO Journal · doi:10.15252/embj.201796697 · Cited by 1,646
Fridman, J. S., & Lowe, S. W. (2003) · Oncogene · doi:10.1038/sj.onc.1207116 · Cited by 1,401 · cited 1×
“The induction of apoptosis can be subdivided into either intrinsic apoptosis, triggered by p53 in response to cellular injuries [29] or extrinsic apoptosis induced upon death ligand binding to a death receptor.”
BackgroundCatalytic activity of the caspase-8–FLIPL complex inhibits RIPK3-dependent necrosis
Oberst, A., Dillon, C. P., Weinlich, R., McCormick, L. L., Fitzgerald, P., Pop, C., Hakem, R., Salvesen, G. S., & Green, D. R. (2011) · Nature · doi:10.1038/nature09852 · Cited by 1,278
The apoptosome: Signalling platform of cell death
Riedl, S. J., & Salvesen, G. S. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2153 · Cited by 1,097 · cited 1×
“Active procaspase-9 promotes further activation of caspases-3, -6, and -7, which eventually execute apoptosis [33,77].”
BackgroundApo2L/TRAIL-Dependent Recruitment of Endogenous FADD and Caspase-8 to Death Receptors 4 and 5
Kischkel, F. C., Lawrence, D. A., Chuntharapai, A., Schow, P., Kim, K. J., & Ashkenazi, A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80212-5 · Cited by 975 · cited 1×
“In cells that express both death-inducing TRAIL-Rs, heterocomplexation was observed [225], although it is still obscure whether this phenomenon has a unique signalling function.”
BackgroundExploring the TRAILs less travelled: TRAIL in cancer biology and therapy
von Karstedt, S., Montinaro, A., & Walczak, H. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.28 · Cited by 556 · cited 4×
“Moreover, activation of mitogen-activated protein kinase (MAPK) [173,174] and tyrosine kinase Src and phosphoinositide 3-kinase (PI3K) pathways [175] through this complex II have been described [14].”
BackgroundMethodInfluentialXIAP discriminates between type I and type II FAS-induced apoptosis
Jost, P. J., Grabow, S., Gray, D., McKenzie, M. D., Nachbur, U., Huang, D. C. S., Bouillet, P., Thomas, H. E., Borner, C., Silke, J., et al. (2009) · Nature · doi:10.1038/nature08229 · Cited by 482
The Long Form of FLIP Is an Activator of Caspase-8 at the Fas Death-inducing Signaling Complex
Micheau, O., Thome, M., Schneider, P., Holler, N., Tschopp, J., Nicholson, D. W., Briand, C., & Grütter, M. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206882200 · Cited by 482
Bratton, S. B., Walker, G., Srinivasula, S. M., Sun, X., Butterworth, M., Alnemri, E. S., & Cohen, G. M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.5.998 · Cited by 406
TAK1 activates AMPK‐dependent cytoprotective autophagy in TRAIL‐treated epithelial cells
Herrero‐Martín, G., Høyer‐Hansen, M., García‐García, C., Fumarola, C., Farkas, T., López‐Rivas, A., & Jäättelä, M. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.8 · Cited by 400 · cited 1×
“For cytoprotective TRAIL-induced autophagy, the activation of TRAF2- and RIPK1-mediated MAPK8/c-Jun N-terminal kinases (JNK) signalling [212] and AMPK signalling [213] was reported.”
BackgroundJones, J. A., Mato, A. R., Wierda, W. G., Davids, M. S., Choi, M., Cheson, B. D., Furman, R. R., Lamanna, N., Barr, P. M., Zhou, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30909-9 · Cited by 383
Dickens, L. S., Boyd, R. S., Jukes-Jones, R., Hughes, M. A., Robinson, G. L., Fairall, L., Schwabe, J. W. R., Cain, K., & MacFarlane, M. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.05.004 · Cited by 349 · cited 10×
“Caspase-8 and cellular FLICE-like IL-1β-converting enzyme-inhibitory protein long/short (c-FLIPL/S), are recruited to TRAIL-Rs via a homotypic interaction between the death domains (DDs) within the receptor and the adapter molecule Fas-associated death domain (FADD) [48,49].”
BackgroundInfluentialSurvival Function of the FADD-CASPASE-8-cFLIPL Complex
Dillon, C. P., Oberst, A., Weinlich, R., Janke, L. J., Kang, T.-B., Ben-Moshe, T., Mak, T. W., Wallach, D., & Green, D. R. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.03.010 · Cited by 331
White, E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026120 · Cited by 320
Hughes, M. A., Powley, I. R., Jukes-Jones, R., Horn, S., Feoktistova, M., Fairall, L., Schwabe, J. W. R., Leverkus, M., Cain, K., & MacFarlane, M. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.02.023 · Cited by 257 · cited 2×
“Depending on the isoform, c-FLIP can act on caspase-8 in an antiapoptotic or proapoptotic manner [54].”
BackgroundDeath receptors as targets in cancer
Micheau, O., Shirley, S., & Dufour, F. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12238 · Cited by 189
Fricker, N., Beaudouin, J., Richter, P., Eils, R., Krammer, P. H., & Lavrik, I. N. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201002060 · Cited by 154 · cited 1×
“Both splice variants, c-FLIPS and c-FLIPL can inhibit the activation of caspase-8 at the DISC when overexpressed [58,59,61].”
BackgroundHuang, K., Zhang, J., O’Neill, K. L., Gurumurthy, C. B., Quadros, R. M., Tu, Y., & Luo, X. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.711051 · Cited by 136 · cited 1×
“MOMP is enabled by caspase-8-mediated cleavage of the Bcl-2 homology (BH)3-only protein (Bid) generating truncated Bid (tBid) [73], which translocates to the mitochondria and eventually activates the mitochondrial cascade (intrinsic apoptosis) by generating an oligomerisation [74,75] of Bcl-2-associated X protein (Bax…”
BackgroundKaplan-Lefko, P. J., Graves, J. D., Zoog, S. J., Pan, Y., Wall, J., Branstetter, D. G., Moriguchi, J., Coxon, A., Huard, J. N., Xu, R., et al. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.8.11264 · Cited by 126
The linear ubiquitin chain assembly complex regulates TRAIL‐induced gene activation and cell death
Lafont, E., Kantari‐Mimoun, C., Draber, P., De Miguel, D., Hartwig, T., Reichert, M., Kupka, S., Shimizu, Y., Taraborrelli, L., Spit, M., et al. (2017) · The EMBO Journal · doi:10.15252/embj.201695699 · Cited by 114 · cited 14×
“TRAF2 recruits cellular inhibitor of apoptosis protein 1/2 (cIAP1/2) which in turn trigger the ubiquitination of RIPK1 and therefore recruitment of linear ubiquitin chain assembly complex (LUBAC) [41].”
BackgroundInfluentialSchleich, K., Buchbinder, J. H., Pietkiewicz, S., Kähne, T., Warnken, U., Öztürk, S., Schnölzer, M., Naumann, M., Krammer, P. H., & Lavrik, I. N. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.137 · Cited by 86 · cited 10×
“Caspase-8 and cellular FLICE-like IL-1β-converting enzyme-inhibitory protein long/short (c-FLIPL/S), are recruited to TRAIL-Rs via a homotypic interaction between the death domains (DDs) within the receptor and the adapter molecule Fas-associated death domain (FADD) [48,49].”
BackgroundInfluential
Cited by
Strategies to tackle RAS-mutated metastatic colorectal cancer
Patelli, G., Tosi, F., Amatu, A., Mauri, G., Curaba, A., Patanè, D. A., Pani, A., Scaglione, F., Siena, S., & Sartore-Bianchi, A. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100156 · Cited by 86
“(DR4) and TRAIL-R2 (DR5), the expression of which was found higher in KRAS MT tumors.(113) A phase I trial is now recruiting RAS MT mCRC patients to receive eftozanermin monotherapy or combined with FOLFIRI and bevacizumab (NCT03082209).”
BackgroundIntracranial delivery of synthetic mRNA to suppress glioblastoma
Peng, H., Guo, X., He, J., Duan, C., Yang, M., Zhang, X., Zhang, L., Fu, R., Wang, B., Wang, D., et al. (2022) · Molecular Therapy - Oncolytics · doi:10.1016/j.omto.2021.12.010 · Cited by 30
Therapeutics Targeting the Core Apoptotic Machinery
Hamilton, C., Fox, J. P., Longley, D. B., & Higgins, C. A. (2021) · Cancers · doi:10.3390/cancers13112618 · Cited by 26
Metadata
- Authors
- Kretz, A.-L., Trauzold, A., Hillenbrand, A., Knippschild, U., Henne-Bruns, D., von Karstedt, S., & Lemke, J.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-03-30
- Volume
- 11
- Issue
- 4
- Pages
- 456
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2925499610
- Cited by
- 70
- References
- 32
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.